What's in Woman's's pipeline?

Woman's has 6 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Woman's's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, AstraZeneca, Eli Lilly and Company, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/woman-s.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Woman's — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Woman's pipeline: 1 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Dexamethasone Mouthwash	Dexamethasone Mouthwash	marketed	Corticosteroid	Glucocorticoid receptor	Dermatology / Oral Medicine
DAPA/MET XR	DAPA/MET XR	phase 3	SGLT2 inhibitor + biguanide combination	SGLT2; metformin (mitochondrial complex I)	Diabetes
EQW plus DAPA	EQW plus DAPA	phase 3	GLP-1 receptor agonist + SGLT2 inhibitor combination	GLP-1 receptor; SGLT2	Diabetes
Saxagliptin-Metformin XR	Saxagliptin-Metformin XR	phase 3	DPP-4 inhibitor / Biguanide combination	DPP-4 enzyme; metformin targets mitochondrial glycerophosphate dehydrogenase and AMPK	Diabetes
Metformin XR plus liraglutide	Metformin XR plus liraglutide	phase 3	Biguanide + GLP-1 receptor agonist combination	AMPK (metformin); GLP-1 receptor (liraglutide)	Diabetes
Exenatide once weekly (EQW )	Exenatide once weekly (EQW )	phase 3	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)	Diabetes

Therapeutic area mix

Diabetes · 5
Dermatology / Oral Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Sanofi · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Pfizer · 2 shared drug classes
Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
AbbVie · 2 shared drug classes
Amsterdam UMC, location VUmc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Woman's:

Cite this brief

Drug Landscape (2026). Woman's — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/woman-s. Accessed 2026-05-17.